Why are tumour blood vessels abnormal and why is it important to know?
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Tumour blood vessels differ from their normal counterparts for reasons that have received little attention. We report here that they are of at least six distinct types, we describe how each forms, and, looking forward, encourage the targeting of tumour vessel subsets that have lost their vascular endothelial growth factor-A (VEGF-A) dependency and so are likely unresponsive to anti-VEGF-A therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Although many in vitro microvessel models have been developed, none of them can actually reproduce the architecture of capillaries seen in a tumor [217,218].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [217]
Experimental — accuracy not yet measuredIn the citing paper
“The vasculature of tumors is very different from the blood vessels that supply healthy tissues, especially in terms of heterogeneity, permeability, multidirectional blood flow, and unordered distribution throughout the tumor160.”
From Tumor-on-a-chip: from bioinspired design to biomedical application (2021) · cites this paper as [160]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187 · cited 1×
“Furthermore, recent successes with agents that block VEGF-A or its receptors have supported Folkman’s (1971) thesis that anti-angiogenesis can be a useful supplement to traditional tumour therapy.”
BackgroundTumors: Wounds That Do Not Heal
Flier, J. S., Underhill, L. H., & Dvorak, H. F. (1986) · New England Journal of Medicine · doi:10.1056/nejm198612253152606 · Cited by 4,391 · cited 1×
“As was noted more than 20 years ago, tumour angiogenesis shares many analogies with wound healing (Dvorak, 1986).”
BackgroundSelf-citationTransplacental Carcinogenesis by Stilbestrol
Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197108122850711 · Cited by 2,640
Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis
Hellström, M., Phng, L.-K., Hofmann, J. J., Wallgard, E., Coultas, L., Lindblom, P., Alva, J., Nilsson, A.-K., Karlsson, L., Gaiano, N., et al. (2007) · Nature · doi:10.1038/nature05571 · Cited by 1,775 · cited 1×
“…of endothelial cells: non-dividing ‘tip’ cells at the leading edge that extend filopodia and sprouts in response to VEGF-A gradients and ‘stalk’ cells that follow behind, divide and exhibit reduced filopodia and sprouting because of signalling through the Notch/delta 4 axis (Hellstrom et al, 2007).”
BackgroundBergers, G., Song, S., Meyer-Morse, N., Bergsland, E., & Hanahan, D. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17929 · Cited by 1,370 · cited 1×
“…that anti-VEGF/VEGFR approaches have effectively treated mouse tumours at early stages of their development, but have proved to be less successful in treating established mouse tumours that contain large numbers of more mature, smooth muscle-cell-coated blood vessels (Bergers et al, 2003).”
BackgroundBergers, G., Song, S., Meyer-Morse, N., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200317929 · Cited by 1,192
Lessons from phase III clinical trials on anti-VEGF therapy for cancer
Jain, R. K., Duda, D. G., Clark, J. W., & Loeffler, J. S. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0403 · Cited by 1,039 · cited 2×
“Agents that neutralise VEGF (e.g., Avastin, VEGF-TRAP) or its receptors have provided proof of principle that anti-angiogenesis can be a useful adjunct to tumour therapy (Jain et al, 2006).”
BackgroundRuhrberg, C., Gerhardt, H., Golding, M., Watson, R., Ioannidou, S., Fujisawa, H., Betsholtz, C., & Shima, D. T. (2002) · Genes & Development · doi:10.1101/gad.242002 · Cited by 914 · cited 2×
“Mice engineered to express only VEGF-A120 develop to term but generate a capillary network with larger-sized vessels and fewer branch points (Ruhrberg et al, 2002).”
BackgroundLee, S., Jilani, S. M., Nikolova, G. V., Carpizo, D., & Iruela-Arispe, M. L. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200409115 · Cited by 703 · cited 2×
“Similar large, MV-like vessels can be generated by still smaller VEGF-As that result from matrix metalloprotease cleavage (Lee et al, 2005).”
BackgroundVasculogenic Mimicry and Tumor Angiogenesis
Folberg, R., Hendrix, M. J. C., & Maniotis, A. J. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64739-6 · Cited by 684 · cited 1×
“…and DV result, respectively, from arteriogenesis and venogenesis. aIn addition, red blood-cell-filled spaces lined by tumour cells rather than by vascular endothelium have been described in some tumours, particularly ocular melanomas, and are referred to as ‘vascular mimicry’ (Folberg et al, 2000).”
Background
Cited by
Items 201–300 of 612
Zhang, W., Wang, L., Xiao, F., Wei, Y., Ke, W., & Xin, H.-B. (2012) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.112.300185 · Cited by 38
Welter, M., Fredrich, T., Rinneberg, H. H., & Rieger, H. (2016) · PLoS ONE · doi:10.1371/journal.pone.0161267 · Cited by 44
“In solid tumors necrotic regions and regions of low microvessel density (MVD) may occur, whereas tumor blood vessels are more abundant at the tumor-host interface [2].”
BackgroundBaradaran, A., Asadzadeh, Z., Hemmat, N., Baghbanzadeh, A., Shadbad, M. A., Khosravi, N., Derakhshani, A., Alemohammad, H., Nour, M. A., Safarpour, H., et al. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112588 · Cited by 42
RetractedUltrasound super-resolution imaging for differential diagnosis of breast masses
Zhang, G., Lei, Y.-M., Li, N., Yu, J., Jiang, X., Yu, M., Hu, H.-M., Zeng, S., Cui, X., & Ye, H.-R. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1049991 · Cited by 37
“Microvascular flow within the mass does not follow a constant and unidirectional path (16).”
BackgroundIntermedin Enlarges the Vascular Lumen by Inducing the Quiescent Endothelial Cell Proliferation
Wang, L., Xiao, F., Kong, L., Wang, D., Li, H., Wei, Y., Chun, T., Zhao, H., Zhang, T., Cao, G., et al. (2017) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.310317 · Cited by 37
Askaner, K., Rydelius, A., Engelholm, S., Knutsson, L., Lätt, J., Abul‐Kasim, K., & Sundgren, P. C. (2018) · Journal of Neuroradiology · doi:10.1016/j.neurad.2018.09.006 · Cited by 36
Su, X., Ma, B., Hu, J. X., Yu, T., Zhuang, W., Yang, L., Li, G., & Wang, Y. (2018) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.8b00671 · Cited by 37
Smith, D. A., & Rowland, M. (2019) · Drug Metabolism and Disposition · doi:10.1124/dmd.118.085951 · Cited by 37
“The blood supply of tumors is not regular when compared with normal tissue (Nagy et al., 2009).”
BackgroundCındıl, E., Şendur, H. N., Cerit, M. N., Dağ, N., Erdoğan, N., Çelebi, F., Öner, Y., & Tali, T. E. (2020) · Neuroradiology · doi:10.1007/s00234-020-02522-9 · Cited by 35
“Neoangiogenesis characterized by newly formed, structurally abnormal serpentine vessels induces leaky capillaries [35] and is the major cause of rCBV increase in the peritumoral area of HGGs [6, 9, 30, 36, 37].”
BackgroundThe Role of Complement in Angiogenesis
Markiewski, M. M., Daugherity, E. A., Reese, B., & Karbowniczek, M. (2020) · Antibodies · doi:10.3390/antib9040067 · Cited by 44
“As a result, the vasculature of tumors is leaky and inefficient [20].”
BackgroundMiller, C. L., Sagiv-Barfi, I., Neuhöfer, P., Czerwinski, D. K., Artandi, S. E., Bertozzi, C. R., Levy, R., & Cochran, J. R. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.10.012 · Cited by 36
Dehydro-α-lapachone, a plant product with antivascular activity
Garkavtsev, I., Chauhan, V. P., Wong, H. K., Mukhopadhyay, A., Glicksman, M. A., Peterson, R. T., & Jain, R. K. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1104225108 · Cited by 40
Logghe, T., van Zwol, E., Immordino, B., den Cruys, K. V., Peeters, M., Giovannetti, E., & Bogers, J. (2024) · Cancers · doi:10.3390/cancers16030505 · Cited by 42
“These findings confirm the idea that local HT alone could promote tumor angiogenesis [79].”
BackgroundEngineering tissue‐specific blood vessels
Herron, L. A., Hansen, C. S., & Abaci, H. E. (2019) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10139 · Cited by 35
“One class of tumor vessels has significantly fewer pericytes than the comparable healthy vessels.(98) Tumor vessels that are surrounded by more pericytes have irregular ordering.”
BackgroundIljaž, J., Wrobel, L. C., Hriberšek, M., & Marn, J. (2019) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2019.103367 · Cited by 39
“It is difficult to exactly model the thermoregulation response of blood perfusion rate due to local vascular dilation or contraction because of the lack of validated models, especially for tumour tissue that has a different vascular system [54, 55] and reacts to temperature changes differently [21, 22].”
BackgroundMicrophysiological Systems as Organ-Specific In Vitro Vascular Models for Disease Modeling
Nam, U., Lee, S., Ahmad, A., Yi, H., & Jeon, J. S. (2024) · BioChip Journal · doi:10.1007/s13206-024-00152-4 · Cited by 39
“For instance, within similar microvessel systems, the blood–brain barrier of the neurovascular system is highly impermeable to block cytotoxic materials, whereas the tumor microvascular system is usually leaky [1, 2].”
Injectable nanorobots for precision cancer therapy: motion-enhanced drug delivery
Gao, Z., Yang, Z., Xu, W., Luo, M., & Guan, J. (2025) · Chemical Society Reviews · doi:10.1039/d5cs00596e · Cited by 41
Huang, H., Lu, J., Wu, J., Ding, Z., Chen, S., Duan, L., Cui, J., Chen, F., Kang, D., Qi, L., et al. (2018) · Scientific Reports · doi:10.1038/s41598-017-18453-0 · Cited by 33
Ternifi, R., Wang, Y., Polley, E. C., Fazzio, R. T., Fatemi, M., & Alizad, A. (2021) · IEEE Transactions on Medical Imaging · doi:10.1109/tmi.2021.3101669 · Cited by 33
Multi-biomarker pattern for tumor identification and prognosis
Rodríguez‐Enríquez, S., Pacheco-Velázquez, S. C., Gallardo‐Pérez, J. C., Marín‐Hernández, Á., Aguilar-Ponce, J. L., Ruíz‐García, E., RuizGodoy-Rivera, L. M., Meneses-García, A., & Moreno‐Sánchez, R. (2011) · Journal of Cellular Biochemistry · doi:10.1002/jcb.23224 · Cited by 34
“5–10mmHg in the hypoxic regions [reviewed in Höckel and Vaupel, 2001; Toffoli and Michielis, 2008] is a recurrent feature associated with an inefficient, chaotic, and fragile neo-vasculature [Nagy et al., 2009].”
BackgroundInfluentialRole of small interfering RNA (siRNA) in targeting ocular neovascularization: A review
Supe, S., Upadhya, A., & Singh, K. (2020) · Experimental Eye Research · doi:10.1016/j.exer.2020.108329 · Cited by 31
Kalot, R., Mhanna, R., & Talhouk, R. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108156 · Cited by 32
Probe-based three-dimensional confocal laser endomicroscopy of brain tumors: technical note
Belykh, E. G., Patel, A., Miller, E. J., Bozkurt, B., Yağmurlu, K., Woolf, E. C., Scheck, A. C., Eschbacher, J. M., Nakaji, P., & Preul, M. C. (2018) · Cancer Management and Research · doi:10.2147/cmar.s165980 · Cited by 31
MicroRNAs and Tumor Vasculature Normalization: Impact on Anti-Tumor Immune Response
Matejuk, A., Collet, G., Nadim, M., Grillon, C., & Kieda, C. (2013) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-013-0231-4 · Cited by 30
“Tumor vessels are highly irregular; the junctions among endothelial cells and connective tissue cells such as perivascular cells are loose, leading to leaky vascular structure with multiple fenestrations (Fukumura et al. 2010; Nagy et al. 2009).”
BackgroundKoyama, S., Matsunaga, S., Imanishi, M., Maekawa, Y., Kitano, H., Takeuchi, H., & Tomita, S. (2017) · Scientific Reports · doi:10.1038/srep45621 · Cited by 31
Antiangiogenic therapy and immune checkpoint blockade go hand in hand
Campesato, L. F., & Merghoub, T. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.10.12 · Cited by 29
“This creates zones of ischemia and ultimately necrosis as tumors outgrow their blood supply (4).”
BackgroundApplications of Polymers for Organ-on-Chip Technology in Urology
Gălățeanu, B., Hudiță, A., Bîru, E. I., Iovu, H., Zaharia, C., Simsensohn, E., Costache, M., Petca, R., & Jinga, V. (2022) · Polymers · doi:10.3390/polym14091668 · Cited by 32
Tumor-derived VEGF modulates hematopoiesis
Xue, Y., Chen, F., Zhang, D., Lim, S., & Cao, Y. (2009) · Vascular Cell · doi:10.1186/2040-2384-1-9 · Cited by 31
Chen, X., Li, Z., Zhu, J., Xia, H.-T., & Zhou, H. (2020) · DNA and Cell Biology · doi:10.1089/dna.2020.5667 · Cited by 29
“VEGFA is an angiogenesis stimulator and overexpressed in majority malignancies with poor prognosis, which plays a significant role in tumor invasiveness, metastasis, increased vascular density, and recurrence (Nagy et al., 2009) (Kerbel, 2008; Lacal and Graziani, 2018).”
BackgroundAsiry, S., Kim, G., Filippou, P. S., Sanchez, L. R., Entenberg, D. R., Marks, D. K., Oktay, M. H., & Karagiannis, G. S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.654877 · Cited by 30
Hann, E., Malagu, K., Stott, A. J., & Vater, H. D. (2022) · Progress in medicinal chemistry · doi:10.1016/bs.pmch.2022.04.002 · Cited by 38
Bahramsoltani, M., Spiegelaere, W. D., Janczyk, P., Hiebl, B., Cornillie, P., & Plendl, J. (2010) · Clinical Hemorheology and Microcirculation · doi:10.3233/ch-2010-1345 · Cited by 30
Kim, J., Jung, S.-Y., Kwon, Y.-H., Lee, S., Lee, J., Lee, B., & Kwon, S. (2012) · Phytotherapy Research · doi:10.1002/ptr.3722 · Cited by 29
“Tumor–stroma interaction enhances neovascularization through angiogenic factors, such as vascular epithelial growth factor (VEGF) (Ferrara, 2000; Nagy et al., 2009; Saharinen et al., 2011) and activated Akt/eNOS signaling.”
BackgroundDendrimer-based magnetic resonance imaging agents for brain cancer
Ding, L., Lyu, Z., Dhumal, D. M., Kao, C., Bernard, M., & Peng, L. (2018) · Science China Materials · doi:10.1007/s40843-018-9323-6 · Cited by 29
Use of Antiangiogenic Therapies in Pediatric Solid Tumors
Ollauri-Ibáñez, C., & Astigarraga, I. (2021) · Cancers · doi:10.3390/cancers13020253 · Cited by 28
Liu, J., Meng, Z., Xu, T., Kuerban, K., Wang, S., Zhang, X., Fan, J., Ju, D., Tian, W., Huang, X., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.845217 · Cited by 29
Schaier, M., Theiner, S., Baier, D., Braun, G., Berger, W., & Koellensperger, G. (2023) · JACS Au · doi:10.1021/jacsau.2c00571 · Cited by 30
Engineering approaches in siRNA delivery
Barba, A. A., Cascone, S., Caccavo, D., Lamberti, G., Chiarappa, G., Abrami, M., Grassi, G., Grassi, M., Tomaiuolo, G., Guido, S., et al. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.02.032 · Cited by 29
“Just to mention few concepts, which are not within the purpose of this review, tumors have an irregular and abnormal vasculature (Nagy et al., 2009) and a high interstitial fluid pressure (Heldin et al., 2004).”
BackgroundPredicting tumour response to anti-PD-1 immunotherapy with computational modelling
Valentinuzzi, D., Simončič, U., Uršič, K., Vrankar, M., Turk, M., & Jeraj, R. (2018) · Physics in Medicine and Biology · doi:10.1088/1361-6560/aaf96c · Cited by 26
Mühlberger, M., Unterweger, H., Band, J., Lehmann, C. H. K., Heger, L., Dudziak, D., Alexiou, C., Lee, G., & Janko, C. (2020) · Cells · doi:10.3390/cells9020342 · Cited by 32
Zhang, L., Huang, J., Buratto, D., Han, P., Yang, Z., & Zhou, R. (2023) · Aggregate · doi:10.1002/agt2.434 · Cited by 25
Extracellular matrix re-normalization to improve cold tumor penetration by oncolytic viruses
Soko, G. F., Kosgei, B. K., Meena, S. S., Ng, Y. J., Liang, H., Zhang, B., Liu, Q., Xu, T., Hou, X., & Han, R. P. S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1535647 · Cited by 33
Dueholm, M., Hjorth, I. M. D., Dahl, K., Pedersen, L., & Ørtoft, G. (2019) · Maturitas · doi:10.1016/j.maturitas.2019.01.017 · Cited by 25
Ferroni, G., Sabeti, S., Abdus-Shakur, T., Scalise, L., Carter, J. M., Fazzio, R. T., Larson, N. B., Fatemi, M., & Alizad, A. (2023) · Breast Cancer Research · doi:10.1186/s13058-023-01670-z · Cited by 25
“This is in agreement with prior studies that have shown that as tumor expands in size, more tortuous vessels with increased diameter are seen in the periphery rather than the center of the tumor [22, 50], suggesting that averaging these biomarkers has less diagnostic value than their maxima.”
BackgroundResultSuchánková, P., Kukleva, E., Štamberg, K., Nykl, P., Vlk, M., & Kozempel, J. (2020) · RSC Advances · doi:10.1039/c9ra08953e · Cited by 24
Texture Analysis of Breast DCE-MRI Based on Intratumoral Subregions for Predicting HER2 2+ Status
Lu, H., & Yin, J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00543 · Cited by 25
Enhancing Combined Immunotherapy and Radiotherapy through Nanomedicine
Hagan, C. T., Mi, Y., Knape, N. M., & Wang, A. Z. (2020) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.0c00520 · Cited by 26
Targeting TRPV1 for Cancer Pain Relief: Can It Work?
SZALLASI, A. (2024) · Cancers · doi:10.3390/cancers16030648 · Cited by 30
Nonogaki, S., Campos, H. G. D. A., Butugan, O., Soares, F. A., Mangone, F. R., Torloni, H., & Brentani, M. M. (2010) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2010.141 · Cited by 26
“Of note, several of these growth factors were also elevated in both hemangiomas and in tumor-associated blood vessels (8,20).”
BackgroundAntiangiogenic Activities of 2,5-Dimethyl-Celecoxib on the Tumor Vasculature
Virrey, J. J., Liu, Z., Cho, H.-Y., Kardosh, A., Golden, E. B., Louie, S. G., Gaffney, K. J., Petasis, N. A., Schönthal, A. H., Chen, T. C., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0652 · Cited by 24
“The vasculature within the tumor has different morphologic and functional characteristics compared with normal, systemic blood vessels (4).”
BackgroundInfluentialEffects of conventional neoadjuvant chemotherapy for breast cancer on tumor angiogenesis
Luengo‐Gil, G., González‐Billalabeitia, E., Cháves-Benito, A., Martínez, E. G., Garre, E. G., Vicente, V., & de la Peña, F. A. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3421-4 · Cited by 27
Li, Y., Ma, A., Johnson, W. E., Eng, C., De, S., Jiang, S., Li, Z., Spakowicz, D. J., & Ma, Q. (2025) · Nature Methods · doi:10.1038/s41592-025-02807-y · Cited by 27
“Tumors tend to have chaotic circulation and are immune privileged 42 , which could lead to microbe deposition and longer persistence.”
Fan, W. X., Chen, X., Cheng, F. Y., Cheng, Y. B., Xu, T., Zhu, W. B., Zhu, X. L., Li, G. J., & Li, S. (2018) · Medicine · doi:10.1097/md.0000000000009666 · Cited by 23
Wright, M. D., Romanelli, P., Bravin, A., Duc, G. L., Bräuer‐Krisch, E., Requardt, H., Bartzsch, S. H., Hlushchuk, R., Laissue, J. A., & Djonov, V. (2021) · Cureus · doi:10.7759/cureus.19317 · Cited by 30
“So-called “mother vessels” in tumoral tissue have degraded basement membranes and pericyte detachment [43].”
BackgroundJeswani, G., Chablani, L., Gupta, U. D., Sahoo, R. K., Nakhate, K. T., Taksande, A. G., & Ajazuddin, M. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.11.285 · Cited by 23
Making In Vitro Tumor Models Whole Again
Wu, K. Z., Adine, C., Mitriashkin, A., Aw, B. J. J., Iyer, N. G., & Fong, E. L. S. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202202279 · Cited by 25
Balzarini, P., Benetti, A., Invernici, G., Cristini, S., Zicari, S., Caruso, A., Gatta, L. B., Berenzi, A., Imberti, L., Zanotti, C., et al. (2012) · Laboratory Investigation · doi:10.1038/labinvest.2012.94 · Cited by 25
Factors Influencing the Therapeutic Efficacy of the PSMA Targeting Radioligand 212Pb-NG001
Stenberg, V. Y., Tornes, A. J. K., Nilsen, H. R., Revheim, M.-E. R., Bruland, Ø. S., Larsen, R. H., & Juzeniene, A. (2022) · Cancers · doi:10.3390/cancers14112784 · Cited by 24
Djurhuus, S. S., Schauer, T., Simonsen, C., Toft, B. G., Jensen, A. R. D., Erler, J. T., Røder, M. A., Højman, P., Brasso, K., & Christensen, J. F. (2022) · Physiological Reports · doi:10.14814/phy2.15408 · Cited by 24
Bhattacharya, R., Brown, J. S., Gatenby, R. A., & Ibrahim‐Hashim, A. (2024) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2024.06.003 · Cited by 29
Fernández-Periañez, R., Molina-Privado, I., Rojo, F., Guijarro-Muñoz, I., Alonso-Camino, V., Zazo, S., Compte, M., Álvarez‐Cienfuegos, A., Cuesta, Á. M., Sánchez‐Martín, D., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072957 · Cited by 26
“These structures have been named as “glomeruloid microvascular proliferations”, and represent a type of angiogenic blood vessel [14].”
BackgroundDiversity Models and Applications of 3D Breast Tumor-on-a-Chip
Song, K., Zu, X., Du, Z., Hu, Z., Wang, J., & Li, J. (2021) · Micromachines · doi:10.3390/mi12070814 · Cited by 22
“lumen model Breast ductal model enable simulation of breast duct structure and function dependence on the scaffold and self-organization, low efficiency [42,78,79]”
BackgroundPereira, M., Matuszewska, K., Jamieson, C., & Petrik, J. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.772349 · Cited by 23
“As a result of the rapid vascularization, many tumor vessels have altered morphology, with blind-ends, constrictions, shunts and other malformations (62).”
BackgroundRana, M. M., & Melancon, M. P. (2022) · Biomimetics · doi:10.3390/biomimetics7020077 · Cited by 24
Metformin and Angiogenesis in Cancer - Revisited
Kannarkatt, J., Alkharabsheh, O. A., Tokala, H., & Dimitrov, N. V. (2016) · Oncology · doi:10.1159/000448175 · Cited by 24
Groza, M., Zimța, A., Irimie, A., Achimaș-Cădariu, P., Cenariu, D., Stanta, G., & Berindan‐Neagoe, I. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.29096 · Cited by 23
Co-Culturing of Endothelial and Cancer Cells in a Nanofibrous Scaffold-Based Two-Layer System
Oh, Y.-S., Choi, M.-H., Shin, J.-I., Maza, P. A. M., & Kwak, J.-Y. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21114128 · Cited by 22
“Angiogenic factors secreted by cancer cells modulate proliferation and survival of ECs [1], however, the tumor vasculature is abnormal and dysfunctional [53].”
BackgroundVersatile Vessel-on-a-Chip Platform for Studying Key Features of Blood Vascular Tumors
Llenas, M., Paoli, R., Feiner‐Gracia, N., Albertazzi, L., Samitier, J., & Caballero, D. (2021) · Bioengineering · doi:10.3390/bioengineering8060081 · Cited by 23
“In contrast, during pathological processes, such as tumor development, the vascular system forms abnormal vessel architectures [1].”
BackgroundGu, J., Ternifi, R., Sabeti, S., Larson, N. B., Carter, J. M., Fazzio, R. T., Fatemi, M., & Alizad, A. (2022) · Breast Cancer Research · doi:10.1186/s13058-022-01583-3 · Cited by 20
“Importantly, the structural abnormalities of malignant tumor microvessels are evident not only by high density but also by complexity of the newly formed vessels presenting with irregularity and tortuosity [2, 3].”
BackgroundWeibel, S., Hofmann, E., Basse-Lüsebrink, T. C., Donat, U., Seubert, C., Adelfinger, M., Gnamlin, P., Kober, C., Frentzen, A., Gentschev, I., et al. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-106 · Cited by 24
“This may finally result in a highly disturbed blood flow which does not follow a constant, unidirectional path in tumors resulting in local hyperpermeability or zones of ischaemia [39].”
BackgroundThe Role of Genetically Modified Mesenchymal Stem Cells in Urinary Bladder Regeneration
Snow-Lisy, D. C., Diaz, E. C., Bury, M. I., Fuller, N. J., Hannick, J. H., Ahmad, N., & Sharma, A. K. (2015) · PLoS ONE · doi:10.1371/journal.pone.0138643 · Cited by 20
“Despite this, the over-expression of Cyr61 resulted in unorganized, highly tortuous vessels similar to those seen in developing solid tumors that were leaky in nature and led to the formation of hematomas throughout the bladder.[57, 58] The lack of structural integrity of the blood vessels may have been caused by the…”
BackgroundThe Adhesome Network: Key Components Shaping the Tumour Stroma
Nikolopoulou, P., Koufaki, M. A., & Kostourou, V. (2021) · Cancers · doi:10.3390/cancers13030525 · Cited by 23
“Unlike normal vessels, tumour vessels lack hierarchical organisation and exhibit irregular branching, aberrant density, shunting, incoherent blood flow and leakiness [128], establishing a chaotic vascular network with impaired functionality.”
BackgroundTumors induce coordinate growth of artery, vein, and lymphatic vessel triads
Ruddell, A., Croft, A., Kelly‐Spratt, K. S., Furuya, M. H., & Kemp, C. J. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-354 · Cited by 23
“VEGF-A, placental growth factor), as well as lymphangiogenesis (VEGF-C, −D), although the resulting vessels are highly abnormal relative to those of embryos [17,18], presumably due to aberrant signaling [9,19].”
BackgroundSalavati, H., Pullens, P., Ceelen, W. P., & Debbaut, C. (2023) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2023.107190 · Cited by 20
Targeting angiogenesis: Lessons from 25 years of normalizing tumor vasculature
Subudhi, S., Lee, S., & Jain, R. K. (2026) · Cell · doi:10.1016/j.cell.2026.03.016 · Cited by 31
Pietrzyk, Ł., Korolczuk, A., Matysek, M., Arciszewski, M. B., & Torres, K. (2021) · Cancer Management and Research · doi:10.2147/cmar.s298165 · Cited by 19
“Compared to normal vessels, tumor blood vessels exhibit an abnormal pattern of organization and function.(12) There is growing evidence that this irregular and nonhierarchical tumor neovasculature expresses unique molecules named tumor endothelial markers (TEMs), which can discriminate between typical and atypical blo…”
BackgroundLiu, J., Pan, D., Huang, X., Wang, S., Chen, H., Zhu, Y. Z., & Ye, L. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1225483 · Cited by 20
“Frontiers in Oncology 02 capillaries linking mother vessels (21, 22).”
BackgroundYin, H. R., Frontini, M. J., Arpino, J., Nong, Z., O’Neil, C. H., Xu, Y., Balint, B., Ward, A. D., Chakrabarti, S., Ellis, C. G., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.652222 · Cited by 22
Transforming Growth Factor-β Drives the Transendothelial Migration of Hepatocellular Carcinoma Cells
Koudelková, P., Costina, V., Weber, G., Dooley, S., Findeisen, P., Winter, P., Agarwal, R., Schlangen, K., & Mikulits, W. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18102119 · Cited by 19
Benedetto, P. D., Ruscitti, P., Liakouli, V., Galdo, F. D., Giacomelli, R., & Cipriani, P. (2019) · Molecular Medicine Reports · doi:10.3892/mmr.2019.10429 · Cited by 28
“This would be advantageous in the treatment of cancer, allowing efficient delivery of therapeutics and increasing the responsiveness to VeGF inhibition (61,71).”
RAGE Signaling in Melanoma Tumors
Olaoba, O. T., Kadasah, S. F., Vetter, S. W., & Leclerc, E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21238989 · Cited by 32
“In tumors, endothelial cells from newly formed blood vessels play major roles by supplying tumor cells with the needed oxygen and nutrients [262].”
BackgroundBrocato, T. A., Brown-Glaberman, U. A., Wang, Z., Selwyn, R. G., Wilson, C. M., Wyckoff, E. F., Lomo, L. C., Saline, J. L., Hooda-Nehra, A., Pasqualini, R., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.126518 · Cited by 18
“Tumor vasculature is a chaotic labyrinth of malformed and destabilized blood vessels that are structurally and functionally impaired (32).”
UV emitting nanoparticles enhance the effect of ionizing radiation in 3D lung cancer spheroids
Tran, T. A., Kappelhoff, J., Jüstel, T., Anderson, R. R., & Purschke, M. (2022) · International Journal of Radiation Biology · doi:10.1080/09553002.2022.2027541 · Cited by 20
“Solid tumors typically have hypoxic regions, poorly perfused with well-developed blood vessels (Nagy et al. 2009).”
BackgroundGerwing, M., Hoffmann, E., Kronenberg, K., Hansen, U. J., Masthoff, M., Helfen, A., Geyer, C., Wachsmuth, L., Höltke, C., Maus, B., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1000036 · Cited by 18
“This intratumoral hypoxia stimulates neoangiogenesis and the formation of distorted, unorganized blood vessels, while slower growing 67NR tumors form blood vessels with features closer to physiological blood vessels (25, 26).”
BackgroundEngineered Organic Nanorockets with Light‐Driven Ultrafast Transportability for Antitumor Therapy
Feng, A., Cheng, X., Huang, X., Liu, Y., He, Z., Zhao, J., Duan, H., Shi, Z., Guo, J., Wang, S., et al. (2023) · Small · doi:10.1002/smll.202206426 · Cited by 19
He, Y., Kam, H., Wu, X., Chen, Q., & Lee, S. M. (2023) · Chinese Medicine · doi:10.1186/s13020-023-00786-w · Cited by 20
“However, it has been known that abnormal angiogenesis or uncontrolled growth of blood vessels are hallmarks of many malignant diseases, especially cancer [45].”
BackgroundUnveiling promising targets in gastric cancer therapy: A comprehensive review
Li, W., Wei, J., Cheng, M., & Liu, M. (2024) · Molecular Therapy Oncology · doi:10.1016/j.omton.2024.200857 · Cited by 27
“50 Studies have consistently linked higher VEGF expression with poorer patient prognosis.”
BackgroundAnti-VEGF Therapy in Cancer: A Double-Edged Sword
Gardner, V., Madu, C. O., & Lu, Y. W. (2017) · InTech eBooks · doi:10.5772/66763 · Cited by 26
“Tumor blood vessel can be divided into six general classes: (1) mother vessels, which are enlarged, tortuous, thin-walled, lacking in pericytes, and highly permeable; (2) capillaries, which are similar to normal capillaries; (3) glomeruloid microvascular proliferations, which are tangles of vessels situated within a m…”
BackgroundCharacterization of an Array-Based Dual-Frequency Transducer for Superharmonic Contrast Imaging
Yang, J., Chérin, E., Yin, J., Newsome, I. G., Kierski, T. M., Pang, G., Carnevale, C. A., Dayton, P. A., Foster, F. S., & Demore, C. E. M. (2021) · IEEE Transactions on Ultrasonics Ferroelectrics and Frequency Control · doi:10.1109/tuffc.2021.3065952 · Cited by 18
Zadeh, E. S., Keber, C. U., Dietrich, C. F., Westhoff, C. C., Günter, C., Beutel, B., Alhyari, A., Trenker, C., & Görg, C. (2021) · Journal of Ultrasound in Medicine · doi:10.1002/jum.15730 · Cited by 19
“The reason for the rapid DE with a rapid washout (<120 seconds) in the parenchymal phase could be speculated to be due to the presence of arteriovenous shunting, similar to that found in malignant tissue with tumor neoangiogenesis.(33,34) This phenomenon of decreased enhancement of PPGLs could not be correlated with a…”
ResultG-Quadruplex Regulation of VEGFA mRNA Translation by RBM4
Niu, K., Zhang, X., Song, Q., & Feng, Q. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020743 · Cited by 21
“VEGFA is overexpressed in tumor cells, and VEGFA protein secreted by tumor cells and surrounding stroma induces the formation of new blood vessels, leading to tumor outgrowth, metastasis, and prognosis [38,39].”
BackgroundCooley, M. B., Wegierak, D., & Exner, A. A. (2024) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1957 · Cited by 24
Cui, S., & Pratx, G. (2022) · Medical Physics · doi:10.1002/mp.15642 · Cited by 16
Targeted therapies against breast cancer: Clinical perspectives, obstacles and new opportunities
Nagpal, D., Verma, R., Mittal, V., Jeandet, P., & Kaushik, D. K. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.105049 · Cited by 22
Longobardi, G., Moore, T. L., Conte, C., Ungaro, F., Satchi‐Fainaro, R., & Quaglia, F. (2024) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1990 · Cited by 22
Tumor interstitial fluid: proteomic determination as a possible source of biomarkers.
Baronzio, G., Parmar, G., Baronzio, M., & Kiselevsky, M. V. (2014) · PubMed · Cited by 24
Kannan, P., Kretzschmar, W. W., Winter, H., Warren, D., Bates, R., Allen, P. D., Syed, N., Irving, B., Papież, B. W., Kaeppler, J., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0033 · Cited by 20
“Indeed, tumors havemultiple types of vessels that stem from different growth mechanisms (47, 48), have different sizes, and respond differently to angiogenic factors such as VEGF (49).”
BackgroundInfluentialOptical properties and antiangiogenic activity of a chalcone derivate
Lemes, S. R., Júnior, L. A., Manoel, D. S., de Sousa, M. A. M., Fonseca, R. D., Lima, R. S., Pérez, C. N., Reis, P. R. D. M., Cardoso, C. G., Silveira-Lacerda, E. D. P., et al. (2018) · Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy · doi:10.1016/j.saa.2018.06.099 · Cited by 17
Expression of vascular endothelial growth factor (VEGF) in equine sarcoid
Martano, M., Power, K., Restucci, B., Pagano, I., Altamura, G., Borzacchiello, G., & Maiolino, P. (2018) · BMC Veterinary Research · doi:10.1186/s12917-018-1576-z · Cited by 18
Simón, M., Jørgensen, J. T., Nørregaard, K., & Kjær, A. (2020) · Scientific Reports · doi:10.1038/s41598-020-64617-w · Cited by 17
Metadata
- Authors
- Nagy, J. A., Chang, S.-H., Dvorak, A. M., & Dvorak, H. F.
- Affiliations
- Beth Israel Deaconess Medical Center (US)
- Corresponding author
- Dvorak, H F
- ORCID
- Nagy, J A
- Venue
- British Journal of Cancer
- Published
- 2009-02-24
- Volume
- 100
- Issue
- 6
- Pages
- 865-869
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- PMC
- PMC2661770
- OpenAlex
- W2063556542
- Cited by
- 611
- References
- 38
- Citations by year
- 2026: 30 · 2025: 39 · 2024: 62 · 2023: 47 · 2022: 50 · 2021: 53 · 2020: 61 · 2019: 47 · 2018: 51 · 2017: 48 · 2016: 22 · 2015: 16 · 2014: 12 · 2013: 18 · 2012: 20
- FWCI
- 1.38
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- www.springer.com/tdm (unspecified)
- Locations
- British Journal of Cancer (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Foundation for Cancer Research
- National Heart, Lung, and Blood Institute (R01HL064402, HL-64402)
- National Cancer Institute (P01 CA 92644, P01CA092644)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- tumor vasculature, VEGF-A, anti-VEGF therapy, tumor angiogenesis, anti-angiogenic therapy resistance
- MeSH terms
- Animals, Blood Vessels, Capillaries, Humans, Neoplasms, Neovascularization, Pathologic, Vascular Endothelial Growth Factor A
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.